HSP90AA1 and neoplasm: The xenograft experiment indicated that MPT0G449 suppressed tumor growth by HDAC and HSP90 inhibition, suggesting that a dual HDAC and HSP90 inhibitor could be a potent strategy for anticancer treatment.